Emergence of protein kinase CK2 as a key target in cancer therapy

BioFactors

Volumn 36, Issue 3, 2010, Pages 187-195

  Trembley, Janeen H ^a   Chen, Zhong ^b   Unger, Gretchen ^c   Slaton, Joel ^a,d,e   Kren, Betsy T ^a   Van Waes, Carter ^b   Ahmed, Khalil ^a,d,e  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^c GeneSegues   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Antisense; Cancer; Casein kinase 2; Nanocapsule; Nanoparticle; NF B; Protein kinase CK2; Signaling; SiRNA; Tenascin; Tenfibgen

Indexed keywords

ANTINEOPLASTIC AGENT; CASEIN KINASE II; CISPLATIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NANOCAPSULE; NANOPARTICLE; TENASCIN;

ANTISENSE THERAPY; APOPTOSIS; CANCER CELL; CANCER THERAPY; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEASIBILITY STUDY; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOBLOTTING; IN VIVO STUDY; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

ANIMALS; APOPTOSIS; CASEIN KINASE II; HUMANS; NEOPLASMS; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 77955734928     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.96     Document Type: Review

References (98)

1. Allende J. E., and Allende C. C. (1995) Protein kinase CK2-an enzyme with multiple substrates and a puzzling regulation. FASEB J. 9, 313-323.
2. Ahmed, K. (1999) Nuclear matrix and protein kinase CK2 signaling. Crit. Rev. Eukaryot. Gene Expr. 9, 329-336.
3. Ahmed, K., Gerber D. A., and Cochet C. (2002) Joining the cell survival squad: an emerging role for protein kinase CK2. Trends Cell Biol. 12, 226-230.
4. Pinna, L. A. (2002) Protein kinase CK2: a challenge to canons. J. Cell Sci. 115, 3873-3878.
5. Litchfield, D. W. (2003) Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem. J. 369, 1-15.
6. Pyerin, W., and Ackermann, K. (2003) The genes encoding human protein kinase CK2 and their functional links. Progr. Nucl. Acid Res. Mol. Biol. 74, 239-273.
7. Guerra, B., and Issinger, O.-G. (2008) Protein kinase CK2 in human disease. Curr. Med. Chem. 15, 1870-1886.
8. Tawfic, S., Yu, S., Wang, H., Faust, R., Davis, A., and Ahmed, K. (2001) Protein kinase CK2 signal in neoplasia. Histol. Histopathol. 16, 573-582.
9. Trembley, J. H., Wang, G., Unger, G., Slaton, J., and Ahmed, K. (2009) CK2: a key player in cancer biology. Cell. Mol. Life Sci. 66, 1858-1867.
10. Ahmad, K. A., Wang, G., Unger, G., Slaton, J., and Ahmed, K. (2008) Protein kinase CK2-a key suppressor of apoptosis. Adv. Enzyme Regul. 48, 179-187.
11. Hanahan, D., and Weinberg, R. A. (2000) The hallmarks of cancer. Cell 100, 57-70.
12. Evan, G. I., and Vousden, K. H. (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411, 342-348.
13. Meggio, F., and Pinna, L. A. (2003) One-thousand-and-one substrates of protein kinase CK2? FASEB J. 17, 349-368.
14. Niefind, K., Raaf, J., and Issinger, O.-. G. (2009) Protein kinase CK2: from structure to insights. Cell. Mol. Life Sci. 66, 1800-1816.
15. Chantalat, L., Leroy, D., Filhol, O., Nueda, A., Benitez, M. J., Chambaz, E. M., Cochet, C., and Dideberg, O. (1999) Crystal structure of the human protein kinase CK2 regulatory subunit reveals its zinc finger-mediated dimerization. EMBO J. 18, 2930-2940.
16. Yu, S., Wang, H., Davis, A., and Ahmed, K. (2001) Consequences of CK2 signaling to the nuclear matrix. Mol. Cell. Biochem. 227, 67-71.
17. Wang, H., Davis, A., Yu, S., and Ahmed, K. (2001) Response of cancer cells to molecular interruption of the CK2 signal. Mol. Cell. Biochem. 227, 167-174.
18. Ahmed, K., Yenice, S., Davis, A., and Goueli, S. A. (1993) Association of casein kinase 2 (CK-2) with nuclear chromatin in relation to androgenic regulation of rat prostate. Proc. Natl. Acad. Sci. USA 90, 4426-4430.
19. Faust, M., and Montenarh, M. (2000) Subcellular localization of protein kinase CK2-a key to its function? Cell Tissue Res. 301, 329-340.
20. Filhol, O., and Cochet, C. (2009) Cellular functions of protein kinase CK2: a dynamic affair. Cell. Mol. Life Sci. 66, 1830-1839.
21. Salvi, M., Sarno, S., Marin, O., Meggio, F., Itarte, E., and Pinna, L. A. (2006) Discrimination between the activity of protein kinase CK2 holoenzyme and its catalytic subunits. FEBS Lett. 580, 3948-3952.
22. Guerra, B., Siemer, S., Boldyreff, B., and Issinger, O.-G. (1999) Protein kinase CK2: evidence for a protein kinase CK2β subunit fraction, devoid of the catalytic CK2α subunit in mouse brain and testicles. FEBS Lett. 462, 353-357.
23. Martel, V., Filhol, O., Nueda, A., and Cochet, C. (2002) Dynamic localization/association of protein kinase CK2 subunits in living cells: a role in its cellular regulation? Ann. NY Acad. Sci. 973, 272-277.
24. Olsten, M. E. K., Weber, J. E., and Litchfield, D. W. (2005) CK2 interacting proteins: emerging paradigms for CK2 regulation? Mol. Cell. Biochem. 274, 115-124.
25. Ruzzene, M., and Pinna L. A. (2010) Addiction to protein kinase CK2: a common denominator of diverse cancer cells? Biochim. Biophys. Acta. 1804, 499-504.
26. Miyata, Y. (2009) CK2: the kinase controlling the Hsp90 chaperone machinery. Cell. Mol. Life. Sci. 66, 1840-1849.
27. Barz, T., Ackerman, K., Dubois, G., Eils, R., and Pyerin, W. (2003) Genome-wide expression screens indicate a global role for protein kinase CK2 in chromatin remodeling. J. Cell Sci. 116, 1563-1577.
28. Guo, C., Yu, S., Davis, A. T., Green, J. E., and Ahmed, K. (2001) A potential role of nuclear matrix-associated protein kinase CK2 in protection against drug-induced apoptosis in cancer cells. J. Biol. Chem. 276, 5992-5999.
29. Di Maira, G., Salvi, M., Arrigoni, G., Marin, O., Sarno, S., Brustolon, F., Pinna, L. A., Ruzzene, M. (2005) Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Diff. 12, 668-677.
30. Torres, J., and Pulido, R. (2001) The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J. Biol. Chem. 276, 993-998.
31. Tapia, J. C., Torres, V. A., Rodriguez, D. A., Leyton, L., and Quest, A. F. (2006) Casein kinase 2 (CK2) increases survivin expression via enhanced beta-catenin-T cell factor/lymphoid enhancer binding factordependent transcription. Proc. Natl. Acad. Sci. USA 103, 15079-15084.
32. Wang, G., Ahmad, K. A., and Ahmed, K. (2008) Impact of protein kinase CK2 on inhibitor of apoptosis proteins (IAPs) in prostate cancer cells. Mol. Cell. Biochem. 316, 91-97.
33. McDonnell, M. A., Abedin, M. J., Melendez, M., Platikanova, T. N., Ahmed, K., and Kelekar, A. (2008) Phosphorylation of murine Caspase-9 by the protein kinase CK2 regulates its cleavage by Caspase-8. J. Biol. Chem. 283, 20149-20158.
34. Shin, S., Lee, Y., Kin, W., Ko, H., Choi, H., and Kim, K. (2005) Caspase-2 primes cancer cells for TRAIL-mediated apoptosis by processing procaspase-8. EMBO J. 24, 3532-3542.
35. Wang, G., Ahmad, K. A., and Ahmed, K. (2006) Role of CK2 in regulation of TRAIL induced apoptosis in prostate cancer cells. Canc. Res. 66, 2242-2249.
36. Ravi R. and Bedi A. (2002) Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Canc. Res. 62, 4180-4185.
37. Izeradjene K., Douglas L., Delaney A., and Houghton J. A. (2005) Casein kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines. Oncogene 24, 2050-2058.
38. Ahmad, K. A., Wang, G., and Ahmed, K. (2006) Intracellular hydrogen peroxide production is an upstream event in apoptosis induced by downregulation of CK2 in prostate cancer cells. Mol. Cancer Res. 4, 331-338.
39. Hanif, I. M., Ahmad, K. A., Ahmed, K., and Pervaiz, S. (2009) Involvement of reactive oxygen species in apoptosis induced by pharmacological inhibition of protein kinase CK2. Ann. NY Acad. Sci. 1171, 591-599.
40. Padmanabha, R., Chen-Wu, J. L. P., Hanna, D. E., and Glover, C. V. C. (1990) Isolation, sequencing, and disruption of the yeast CKA2 gene: casein kinase II is essential for viability in S. cerevisiae. Mol. Cell Biol. 10, 4089-4099.
41. Buchou, T., Nernet, M., Blond, O., Jensen, H. H., Pointu, H., Olsen, B. B., Cochet, C., Issinger, O.-G., and Boldyreff, B. (2003) Disruption of the regulatory β subunit of protein kinase CK2 in mice leads to a cell-autonomous defect and early embryonic lethality. Mol. Cell. Biol. 23, 908-915.
42. Lou, D. Y., Dominguez, I., Toselli, P., Landesman-Bollag, E., O'Brien, C., and Seldin, D. C. (2008) The alpha catalytic subunit of protein kinase CK2 is required for mouse embryonic development. Mol. Cell. Biol. 28, 131-139.
43. Seldin, D. C., Lou, D. Y., Toselli, P., Landesman-Bollag, E., and Dominguez, I. (2008) Gene targeting of CK2 catalytic subunits. Mol. Cell. Biochem. 316, 141-147.
44. Wang, H., Yu, S., Davis, A. T., and Ahmed, K. (2003) Cell cycle dependent regulation of protein kinase CK2 signaling to the nuclear matrix. J. Cell. Biochem. 88, 812-822.
45. Yu, S., Davis, A. T., Guo, C., Green, J. E., and Ahmed, K. (1999) Differential targeting of protein kinase CK2 to the nuclear matrix upon transient overexpression of its subunits. J. Cell. Biochem. 74, 127-134.
46. Slaton, J. W., Sloper, D. T., Unger, G., Davis, A., and Ahmed, K. (2004) Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model. Mol. Cancer Res. 2, 712-721.
47. Ahmad, K. A., Wang, G., Slaton, J. W., Unger, G., and Ahmed, K. (2005) Targeting CK2 for cancer therapy. Anticancer Drugs 16, 1037-1043.
48. Ahmed, K., Davis, A. T., Wang, H., Faust, R. A., Yu, S., and Tawfic, S. (2000) Significance of protein kinase CK2 nuclear signaling in neoplasia. J. Cell. Biochem. Supp. 35, 130-135.
49. Kelliher, M. A., Seldin, D. C., and Leder, P. (1996) Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase IIα. EMBO J. 15, 5160-5166.
50. Landesman-Bollag, E., Channavajhala, P. L., Cardiff, R. D., and Seldin, D. C. (1998) p53 deficiency and misexpression of protein kinase CK2 α collaborate in the development of thymic lymphomas in mice. Oncogene 16, 2965-2974.
51. Channavajhala, P., and Seldin, D. C. (2002) Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis. Oncogene 21, 5280-5288.
52. Landesman-Bollag, E., Song, D. H., Romieu-Mourez, R., Sussman, D. J., Cardiff, R. D., Sonenshein, G. E., and Seldin, D. C. (2001) Protein kinase CK2: signaling and tumorigenesis in the mammary gland. Mol. Cell. Biochem. 227, 153-165.
53. Unger, G. M., Davis, A. T., Slaton, J. W., and Ahmed, K. (2004) Protein kinase CK2 as regulator of cell survival: implications for cancer therapy. Curr. Cancer Drug Targets 4, 77-84.
54. Wang, G., Ahmad, K. A., Unger, G., Slaton, J. W., and Ahmed, K. (2006) CK2 signaling in androgen-dependent and-independent prostate cancer. J. Cell. Biochem. 99, 382-391.
55. Gleave, M. E., and Monia, B. (2005) Antisense therapy for cancer. Nat. Rev. Cancer 5, 468-479.
56. Cho-Chung, Y. S. (1996) Protein kinase A-directed antisense restrains cancer growth: sequence-specific inhibition of gene expression. Antisense Nucleic acid Drug Dev. 6, 237-244.
57. Cho, Y. S., Kim, M. K., Tan, L., Srivastava, R., Agrawal, S., and Cho-Chung, Y. S. (2002) Protein kinase A RIα antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hyperphosphorylation. Clin. Canc. Res. 8, 607-614.
58. Ahmed, K. (1994) Significance of the casein kinase system in cell growth and proliferation with emphasis on studies of the androgenic regulation of the prostate. Cell. Mol. Biol. Res. 40, 1-11.
59. Ji, H., Wang, J., Nika, H., Hawke, D., Keezer, S., Ge, Q., Fang, B., Fang, X., Fang, D., Litchfield, D. W., Aldape K., and Lu, Z. (2009) EGF-induced ERK activation promotes CK2-mediated disassociation of a-catenin from β-catenin and transactivation of β-catenin. Mol. Cell 36, 547-559.
60. Kramerov, A. A., Saghizadeh, M., Pan, H., Kabosova, A., Montenarh, M., Ahmed, K., Penn, J. S., Chan, C. K., Hinton, D. R., Grant, M. B., and Ljubimov, A. V. (2006) Expression of protein kinase CK2 in astroglial cells of normal and neovascularized retina. Amer. J. Path. 168, 1722-1736.
61. Kramerov, A. A., Saghizadeh, M., Caballero, S., Shaw, L. C., Li Calzi, S., Bretner, M., Montenarh, M., Pinna, L. A., Grant, M. B., and Ljubimov, A. V. (2008) Inhibition of protein kinase CK2 suppresses angiogenesis and hematopoietic stem cell recruitment to retinal neovascularization sites. Mol. Cell. Biochem. 316, 177-186.
62. Singh, N. N., and Ramji, D. P. (2008) Protein kinase CK2, an important regulator of the inflammatory response? J. Mol. Med. 86, 887-897.
63. Di Maira, G., Brustolon, F., Bertacchini, J., Tosoni, K., Marmiroli, S., Pinna, L. A., and Ruzzene, M. (2007) Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level. Oncogene 26, 6915-6926.
64. Gapany, M., Faust, R. A., Tawfic, S., Davis, A., Adams, G. L., and Ahmed, K. (1995) Association of elevated CK2 activity with aggressive behavior of squamous cell carcinoma of the head and neck. Mol. Med. 1, 659-666.
65. Faust, R. A., Niehans, G. A., Gapany, M., Hoistad, D., Knapp, D., Cherwitz, D., Davis, A., Adams, G. L., and Ahmed, K. (1999) Subcellular immunolocalization of protein kinase CK2 in normal and carcinoma cells. Int. J. Biochem. Cell Biol. 31, 941-949.
66. Laramas, M., Pasquier, D., Filhol, O., Ringeisen, F., Desxotes, J.-L., and Cochet, C. (2007) Nuclear localization of protein kinase CK2 catalytic subunit (CK2α) is associated with poor prognostic factors in human prostate cancer. Eur. J. Cancer 43, 928-934.
67. O-Charoenrat, P., Rusch, V., Talbot, S. G., Sarkaria, I., Viale, A., Socci, N., Ngai, I., Rap, P., and Singh, B. (2004) Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung. Clin. Cancer Res. 10, 5792-5803.
68. Wang, G., Unger, G. M., Ahmad, K. A., Slaton, J. W., and Ahmed, K. (2005) Downregulation of CK2 induces apoptosis in cancer cells: a potential approach to cancer therapy. Mol. Cell. Biochem. 274, 77-84.
69. Pinna, L. A., and Allende, J. E. (2009) Protein kinase CK2: an ugly duckling in the kinome pond. Cell. Molec. Life Sci. 66, 1795-1799.
70. Anderes, K. L., Siddiqui-Jain, A., Streiner, N., Chua, P., Pierre, F., Omori, M., Darjarnia, L., Stansfield, R., Phung, J., Bliesath, J., Ho, C., Drygin, D., O'Brien, S., and Rice, W. (2009) Discovery and characterization of CX-4945 a selective orally bioavailable small molecule inhibitor of protein kinase CK2: phase 1 initiated [abstract]. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research. April 18-22; Denver, CO. Philadelphia (PA), AACR; 2009. Abstract no. 4660.
71. Battistutta, R. (2009) Structural bases of protein kinase CK2 inhibition. Cell. Mol. Life Sci. 66, 1868-1889.
72. Mishra, S., Pertz, V., Zhang, B., Kaur, P., Shimada, H., Groffen, J., Kazimierczuk, Z., Pinna, L. A., and Heisterkamp, N. (2007) Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2. Leukemia 21, 178-180.
73. Zień, P., Bretner, M., Zastapilo, K., Szyszka, R., and Shugar, D. (2003) Selectivity of 4, 5, 6, 7-tetrabromobenzimidazole as an ATP-competitive potent inhibitor of protein kinase CK2 from various sources. Biochem. Biophys. Res. Commun. 306, 129-133.
74. Prudent, R., and Cochet, C. (2009) New Protein Kinase CK2 inhibitors: jumping out of the catalytic box. Chem. Biol. 16, 112-120.
75. Sandholt, I. S., Olsen, B. B., Guerra, B., Issinger, O.-G. (2009) Resorufin: a lead for a new protein kinase CK2 inhibitor. Anticancer Drugs 20, 238-248.
76. Solares, A. M., Santana, A. Baldrón, I., Valenzuela, C., González, C. A., Díaz, A., Castillo, D., Ramos, T., Gómez, R., Alonso, D. F., Herrera, L., Sigman, H., Perea, S. E., Acevedo, B. E., and López-Saura, P. (2009). Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies. BMC Cancer 9, 146.
77. Trembley, J. H., Unger, G., Korman, V. L., Wang, G., Tobolt, D. K., Slaton, J., and Ahmed, K. (2009) Molecular downregulation of CK2 in prostate cancer cells induces apoptosis and shrinks xenograft tumors [Abstract]. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research. April 18-22; Denver, CO. Philadelphia (PA), AACR:2009. Abstract no. 3647.
78. Kren, B. T., Unger, G. M., Sjeklocha, L., Trossen, A. A., Korman, V., Diethelm-Okita, B. M., Reding, M. T., and Steer, C. J. (2009) Nanocapsule-delivered sleeping beauty mediates therapeutic factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice. J. Clin. Invest. 119, 2086-2099.
79. Brown, M. S., Diallo, O. T., Hu, M., Ehsanian, R., Yang, X., Arun, P., Lu, H., Korman, V., Unger, G., Ahmed, K., Van Waes, C., and Chen, Z. (2010) CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50 nm nanocapsules. Clin. Canc. Res. DOI: 10.1158/1078-0432. CCR-09-3200.
80. Sanhai, W. R., Sakamoto, J. H., Canady, R., and Ferrari, M. (2008) Seven challenges for nanomedicine. Nat. Nanotechnol. 3, 242-244.
81. Dominguez, I., Sonenshein, G. E., and Seldin, D. C. (2009) CK2 and its role in Wnt and NF-kB signaling: linking development and cancer. Cell. Mol. Life Sci. 66, 1850-1857.
82. Van Waes, C. (2007) Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin. Canc. Res. 13, 1076-1082.
83. Allen, C. T., Ricker, J. L., Chen, Z., and Van Waes, C. (2007) Role of activated nuclear factorkappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. Head Neck 29, 959-971.
84. Hazem, I. A., Lessard, L., Mes-Masson, A.-M., and Saad, F. (2004) Expression of NFκB in prostate cancer lymph node metastases. Prostate 58, 308-313.
85. Brown, M., Cohen, J., Arun, P., Chen, Z., and Van Waes, C. (2008) NF-kappaB in carcinoma therapy and prevention. Expert Opin. Ther. Targets 12, 1109-1122.
86. Shen, J., Channavajhala, P., Seldin, D. C., and Sonenshein, G. E. (2001) Phosphorylation by the protein kinase CK2 promotes calpain-mediated degradation of IkappaBalpha. J. Immunol. 167, 4919-4925.
87. Romieu-Mourez, R., Landesman-Bollag, E., Seldin, D. C., and Sonenshein, G. E. (2002) Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells. Canc. Res. 62, 6770-6778.
88. Yu, M., Yeh, J., and Van Waes, C. (2006) Protein kinase CK2 mediates inhibitor-kappaB kinase and aberrant nuclear factor-kappaB activation by serum factor (s) in head and neck squamous cell carcinoma cells. Canc. Res. 66, 6722-6731.
89. Wang, D., Westerheide, S. D., Hanson, J. L., and Baldwin, A. S., Jr. (2000) Tumor necrosis factor alpha-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. J. Biol. Chem. 275, 32592-32597.
90. Lee, T. L., Yang, X. P., Yan, B., Friedman, J., Duggal, P., Bagain, L., Dong, G., Yeh, N. T., Wang, J., Zhou, J., Elkahloun, A., Van Waes, C., and Chen, Z. (2007) A novel nuclear factor-kappaB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status. Clin. Cancer Res. 13, 5680-5691.
91. Friedman, J., Nottingham, L., Duggal, P., Pernas, F. G., Yan, B., Ping, X., Yang, P., Chen, Z., and Van Waes, C. (2007) Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer. Clin. Cancer Res. 13, 6568-6578.
92. Keller, D. M., Zeng, X., Wang, Y., Zhang, Q. H., Kapoor, M., Shu, H., Goodman, R., Lozano, G., Zhao, Y., and Lu, H. (2001) A DNA damageinduced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Mol. Cell 7, 283-292.
93. McKendrick, L., Milne, D., and Meek, D. (1999) Protein kinase CK2-dependent regulation of p53 function: evidence that the phosphorylation status of the serine 386 (CK2) site of p53 is constitutive and stable. Mol. Cell. Biochem. 191, 187-199.
94. Prowald, A., Schuster, N., and Montenarh, M. (1997) Regulation of the DNA binding of p53 by its interaction with protein kinase CK2. FEBS Lett. 408, 99-104.
95. Schuster, N., Götz, C., Faust, M., Schneider, E., Prowald, A., Jungbluth, A., and Montenarh, M. (2001) Wild-type p53 inhibits protein kinase CK2 activity. J. Cell. Biochem. 81, 172-183.
96. Van Waes, C., Kozarsky, K. F., Warren, A. B., Kidd, L., Paugh, D., Liebert, M., and Carey, T. E. (1991) The A9 antigen associated with aggressive human squamous carcinoma is structurally and functionally similar to the newly defined integrin alpha 6 beta 4. Cancer Res. 51, 2395-2402.
97. Van Waes, C. (1995) Cell adhesion and regulatory molecules involved in tumor formation, hemostasis, and wound healing. Head Neck 17, 140-147.
98. Schneider, C. C., Hessenauer, A., Montenarh, M., and Götz, C. (2010) p53 is dispensable for the induction of apoptosis after inhibition of protein kinase CK2. Prostate 70, 126-134.